# A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

> **NCT02641392** · PHASE3 · TERMINATED · sponsor: **Celgene** · enrollment: 310 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** GED-0301
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02641392
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-25
- **Primary completion:** 2018-01-04
- **Final completion:** 2018-01-04
- **Target enrollment:** 310 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor following a recommendation from external DMC based on lack of emerging benefit; there were no new emergent safety findings
- **Last updated:** 2019-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641392, "A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02641392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*